SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-282059
Filing Date
2022-11-10
Accepted
2022-11-10 09:11:32
Documents
14
Period of Report
2022-11-10
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d410137d8k.htm   iXBRL 8-K 39325
2 EX-99.1 d410137dex991.htm EX-99.1 28327
6 GRAPHIC g410137g1110035221778.jpg GRAPHIC 1050
  Complete submission text file 0001193125-22-282059.txt   206703

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ikna-20221110.xsd EX-101.SCH 2877
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikna-20221110_lab.xml EX-101.LAB 19503
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikna-20221110_pre.xml EX-101.PRE 12171
8 EXTRACTED XBRL INSTANCE DOCUMENT d410137d8k_htm.xml XML 3654
Mailing Address 50 NORTHERN AVE. BOSTON MA 02210
Business Address 50 NORTHERN AVE. BOSTON MA 02210 857-343-8292
Ikena Oncology, Inc. (Filer) CIK: 0001835579 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40287 | Film No.: 221375258
SIC: 2836 Biological Products, (No Diagnostic Substances)